Global Perphenazine Market Growth 2025-2031

The global Perphenazine market size is predicted to grow from US$ 102 million in 2025 to US$ 125 million in 2031; it is expected to grow at a CAGR of 3.4% from 2025 to 2031.

Perphenazine is a typical antipsychotic drug. Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the US as Trilafon, it has been in clinical use for decades. Perphenazine is roughly five times as potent as chlorpromazine, thus perphenazine is considered a medium-potency antipsychotic.

Global Perphenazine key players include Teva, Sandoz, Endo, Mylan, ZHPHARMA etc. Global top five manufacturers hold a share over 80%.

North America is the largest market, with a share over 50%, followed by Asia-Pacific and Europe, both have a share over 20% percent.

In terms of product, Oral Forms is the largest segment, with a share over 90%. And in terms of application, the largest application is Psychosis followed by Antiemetic.

LP Information, Inc. (LPI) ' newest research report, the “Perphenazine Industry Forecast” looks at past sales and reviews total world Perphenazine sales in 2024, providing a comprehensive analysis by region and market sector of projected Perphenazine sales for 2025 through 2031. With Perphenazine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Perphenazine industry.

This Insight Report provides a comprehensive analysis of the global Perphenazine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Perphenazine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Perphenazine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Perphenazine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Perphenazine.

This report presents a comprehensive overview, market shares, and growth opportunities of Perphenazine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Oral Forms
Injectable Solution

Segmentation by Application:
Psychosis
Antiemetic

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Teva
Sandoz
Endo
Mylan
ZHPHARMA
Shandong Boshan Pharma

Key Questions Addressed in this Report

What is the 10-year outlook for the global Perphenazine market?

What factors are driving Perphenazine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Perphenazine market opportunities vary by end market size?

How does Perphenazine break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.